ArticleFEBS open bio2026
Malformin A1-mediated cytotoxicity in ovarian cancer cells occurs through pyroptosis and autophagy.
Article in FEBS open bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Cytoskeletal proteins play a crucial role in providing mechanical support and regulating key cellular processes such as cell proliferation, migration, and invasion. Cytoskeletal damage has been increasingly regarded as a contributing factor in impairing these cellular processes in cancer. Moreover, induction of cell death pathways has been linked to cytoskeletal destabilization. However, the effect of cytoskeletal disruption on cell death mechanisms in ovarian cancer (OC) remains elusive. Several natural compounds have been demonstrated to initiate cytoskeletal destabilization as a mechanism to promote cell death. We have previously shown that one such natural compound derived from marine sources, Malformin A1 (MA1), exhibits high toxicity toward both cisplatin-sensitive (A2780S) and cisplatin-resistant (A2780CP) OC cell lines. Thus, here we evaluate the impact of cytoskeletal destabilization by MA1 treatment on OC cell death by analyzing the expression levels of apoptosis, autophagy, and DNA damage-related genes. Our findings show MA1 treatment significantly downregulated key cytoskeletal proteins while also decreasing the expression of pro-apoptotic markers, suggesting alternative cell death mechanisms. Autophagy-related analyses demonstrated enhanced LC3BI to LC3BII processing, indicating autophagy activation with elevated γ-H2AX levels confirming substantial DNA damage in MA1-treated cells. Notably, MA1 was able to induce pyroptotic cell death, as evidenced by increased caspase-1 expression. Moreover, molecular docking analysis revealed that MA1 displayed the strongest binding affinity for vimentin, GAPDH, and β-tubulin, providing mechanistic insights into its ability to disrupt cytoskeletal integrity and induce nonapoptotic cell death through multiple pathways, highlighting MA1's potential as a promising therapeutic candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.